Skip to main content
. 2024 Dec 27;17:3033–3044. doi: 10.2147/CCID.S498987

Figure 3.

Figure 3

Hit compounds identified in the original screen underwent further chemical optimization to enhance potency and stability. The resulting optimized compounds were screened with the original compounds for comparison. Screening was performed in SK-MEL-5 cells using 5-point dose response curves. TYR mRNA levels were assessed by bDNA assay (A). Confirmation of the two best hits from the SK-MEL-5 testing was performed in primary human melanocytes (HEMn) (B). Opt 3 was selected as the lead compound and renamed RXI-231.